U.S. Professional Services Stock News

When inflation stories keep circling around energy, food and shipping costs, it can help to focus on something more tangible: the people actually running the businesses you own. Founder-led companies often have leaders with significant personal capital at risk and a long-term mindset that is not tied to quarterly bonus targets. This article looks at how that approach can matter as bond yields move, input costs shift and policy headlines swing. It then highlights 3 standouts from a Top...

Geron Corporation recently expanded its Board of Directors by appointing Patricia S. Andrews and Constantine Chinoporos, both experienced leaders in oncology commercialization and biopharma deal-making. The addition of directors with deep oncology launch and business development backgrounds may be particularly relevant as Geron progresses RYTELO and evaluates future growth options. Next, we’ll explore how Geron’s addition of seasoned oncology and business development leaders could influence...

If you are wondering whether Genpact at around US$37.74 is a bargain or a value trap, the key is to understand what the current price actually reflects. The stock has moved 3.2% over the past week, while sitting on a 9.5% decline over 30 days and an 18.5% fall over the last year. These moves can change how the market views both its growth potential and risk profile. Recent coverage has focused on Genpact's positioning within professional services and how its business mix fits with longer...

In late March 2026, Morgan Stanley downgraded AvalonBay Communities to Equalweight following Q4 results, pointing to guidance that implies almost flat core funds from operations per share this year. While Morgan Stanley cut near-term expectations more than peers, it still highlights AvalonBay’s potential for stronger earnings growth further out. With Morgan Stanley flagging a flat near-term earnings outlook, we’ll now examine how this shift affects AvalonBay’s broader investment narrative...

Why BBB Foods’ latest SEC filing matters for shareholders BBB Foods (NYSE:TBBB) recently filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, giving investors a detailed, audited look at the Mexican hard discount grocer’s operations and financial position. This filing follows the company’s recent stock exchange listing and rapid store expansion in Mexico. It offers a single source for updated financial statements, risk disclosures, and governance information...

Recent analyst activity around Equity LifeStyle Properties (ELS) has picked up, with Mizuho initiating coverage and BofA Securities upgrading the stock, while BMO Capital maintains a supportive stance that may be shaping current investor sentiment. See our latest analysis for Equity LifeStyle Properties. The share price at US$63.99 has a 1-day share price return of 1.15% and a 90-day share price return of 7.02%. However, the 1-year total shareholder return of a 2.68% decline suggests recent...

PTC Therapeutics recently appointed longtime Morgan Stanley healthcare banker Jessica Chutter to its Board of Directors as a Class I director, effective March 24, 2026, with standard outside-director compensation including a US$50,000 annual retainer and expense reimbursement. Her four decades of experience advising biotechnology and pharmaceutical companies on mergers, capital raising, and valuation bring capital-markets depth that could influence how PTC Therapeutics approaches future...

Summit Therapeutics Inc. recently presented data for its investigational bispecific antibody ivonescimab at the 2026 European Lung Cancer Congress in Copenhagen, highlighting progress in multiple Phase III trials across non-small cell lung cancer and colorectal cancer. The company now has 15 announced, ongoing, or completed Phase III studies for ivonescimab, including four Summit-sponsored global trials and ten China-based trials run by partner Akeso Inc., underscoring how extensively this...

Adeia Inc. recently reiterated its full-year 2026 guidance, projecting GAAP revenue of US$395.0 million–US$435.0 million and net income of US$57.2 million–US$80.4 million, while its subsidiaries filed a patent infringement lawsuit against Dish Network over five media and pay-TV patents. The combination of reaffirmed financial targets and active enforcement of its media intellectual property underscores how central licensing and litigation are to Adeia’s business model. We’ll now examine how...

Victoria's Secret & Co. recently reported that its fiscal Q4 and full-year 2025 results came in ahead of both revenue and profit guidance, with comparable sales rising in the high single digits for the quarter and mid single digits for the year. Analysts pointed to strengthening brand resonance as a key driver behind this outperformance, suggesting that the company’s ongoing repositioning around inclusivity and product innovation is gaining traction with core customers. We’ll now examine how...

Flex (NasdaqGS:FLEX) has entered a definitive all cash agreement to acquire Electrical Power Products, also known as EP2. The deal is intended to expand Flex's Critical Power portfolio and its presence in utility and industrial end markets. EP2 adds power distribution and control capabilities that align with Flex's focus on Critical Power solutions. The acquisition is expected to be accretive to adjusted earnings per share in the first full fiscal year after closing. For you as an investor,...

If you are wondering whether Utz Brands at US$7.71 is a bargain or a value trap, the starting point is understanding what the current share price actually reflects. The stock has recently seen a 3.4% gain over 7 days, set against weaker returns of 11.3% over 30 days, 25.1% year to date and 44.9% over 1 year. These moves may signal shifting expectations about risk and future prospects. Recent coverage has focused on how investors are reassessing packaged food names, with Utz Brands often...

Event context and why Liberty Latin America matters now With no single headline event driving Liberty Latin America (LILA) today, attention is on how the stock’s recent returns compare with its fundamentals, including revenue of $4.44b and a net loss of $611.2m. See our latest analysis for Liberty Latin America. Liberty Latin America’s recent share price return of 6.78% over 30 days and 15.01% year to date, from a latest share price of $8.35, sits alongside a 35.11% 1 year total shareholder...

Phibro Animal Health recently reported strong fiscal Q2 2026 results, with earnings per share and revenue topping expectations and highlighting improved profitability and operational progress across its animal health portfolio. At the same time, the company’s integration of Zoetis’ medicated feed additive business and expanding vaccines franchise point to a business mix that is shifting toward higher-value products and broader international reach. With this backdrop of better-than-expected...

Host Hotels & Resorts (NasdaqGS:HST) has been named the winner of Nareit’s 2026 Leader in the Light Award for Operations in the large cap REIT category. The award recognizes the company’s approach to sustainability, resilience, and operational performance across its portfolio. This recognition reflects the integration of environmental and operational priorities into Host’s investment and management practices. Host Hotels & Resorts focuses on owning and operating luxury and upper upscale...

Wondering if Zeta Global Holdings at around US$15.79 is offering value or asking too much? This article walks through what the current price might be saying about the stock. The share price has declined around 1.8% over the last week and 12.5% over the last month, yet it still shows a 20.1% return over the past year and 55.0% over three years, which gives a mixed picture of recent momentum. Recent coverage has focused on Zeta Global Holdings as a software player with a stock that has pulled...

CleanSpark (NasdaqCM: CLSK) has amended its Series A Preferred Stock, replacing recurring quarterly dividends with a one-time special dividend payout. The company has also completed the acquisition of a 300 MW Bitcoin mining campus in Texas. These changes affect both the income profile of preferred shareholders and the scale of CleanSpark's mining footprint. CleanSpark, trading at $8.79, has had mixed share performance, with a 1-year return of 18.6%, a 23.9% decline year to date, and a...

If you are wondering whether Burlington Stores at around US$328.73 is offering good value today, you are not alone. This article focuses squarely on that question. The stock has posted returns of 2.7% over 7 days, 9.4% over 30 days, 10.2% year to date, 39.5% over 1 year, 69.5% over 3 years and 5.0% over 5 years. This naturally raises questions about what is already priced in and what might still be on the table. Recent coverage of Burlington Stores has highlighted how investors are...

Shopee has reached an official profitability milestone, marking a key shift in the economics of Sea's core e commerce business. SeaMoney has reported strong year over year gains in profitability and loan growth, pointing to deeper engagement across its digital financial services. Institutional investor Steve Cohen has increased his stake in Sea (NYSE:SE), signaling renewed interest from a high profile market participant. Sea (NYSE:SE) is trading at $82.28, after a 3.0% gain over the past...

Wondering if Modine Manufacturing at around US$219 per share is still sensibly priced, or if the easy part of the story is already behind it. The stock has posted returns of 1.6% over the last 7 days, 3.3% over 30 days, 55.8% year to date and 202.1% over the past year, with a very large gain of more than 7x over 5 years. Recent coverage has focused on Modine Manufacturing as a high-performing name in the capital goods space, with attention on how its share price history compares to peers and...

Bicara Therapeutics Inc. has reported 2025 results showing a higher net loss of US$137.95 million while simultaneously bolstering its balance sheet through an oversubscribed public offering and filing a US$70.36 million shelf registration for additional common stock. Against this backdrop, the company’s lead candidate ficerafusp alfa secured FDA Breakthrough Therapy Designation and advanced into a pivotal Phase III trial, prompting renewed attention to how Bicara is balancing heavier losses...

Denali Therapeutics (NasdaqGS:DNLI) has regained full global rights to DNL593 for frontotemporal dementia granulin, after Takeda ended its collaboration. DNL593 uses Denali's TransportVehicle technology to deliver progranulin to the brain for patients with FTD-GRN. Denali plans to continue clinical development of DNL593 independently, with Phase 1/2 study results expected by the end of 2026. Denali Therapeutics focuses on treatments for neurodegenerative diseases, an area where current...

In early April 2026, EXL announced a collaboration with Google Cloud to expand AI-led transformation services, helping clients scale enterprise AI, modernize data, and upgrade cloud infrastructure across financial services, healthcare, life sciences, utilities, and retail. A key insight is that EXL is deepening its Google Cloud practice with over 800 trained AI specialists and proven frameworks already used to automate complex, high-volume workflows for large enterprises, particularly in...

If you are wondering whether Pool's current share price lines up with its underlying value, this article walks through the numbers so you can judge that for yourself. Pool last closed at US$202.93, with returns of 0.9% over 7 days, an 8.3% decline over 30 days, an 11.7% decline year to date and a 34.1% decline over 1 year that many investors are watching closely. Over the past few months, coverage of Pool has focused on how the share price performance compares with broader retail...